Plasmablastic lymphoma of the sphenoid bone in an immunocompetent patient: A diagnostic challenge
Indian J Pathol Microbiol. 2023 Nov 9. doi: 10.4103/ijpm.ijpm_944_22. Online ahead of print.ABSTRACTPlasmablastic lymphoma is a rare type of highly aggressive B-cell non-Hodgkin lymphoma that usually occurs in immunocompromised patients and involves chiefly extra-nodal sites such as the oral cavity, jaw, gastrointestinal tract, soft tissue, bone, and skin. People above the age of 50 years are more commonly affected, with male predominance having a survival rate of 8 to 15 months. Here, we describe the case of a 48-year-old man who had an isolated plasmablastic lymphoma of the right sphenoid bone without any immunodeficienc...
Source: Indian Journal of Pathology and Microbiology - February 23, 2024 Category: Pathology Authors: Anurag Singh Vinita Agrawal Alka Singh Source Type: research
The Efficacy of Bepotastine Besilate Compared With Hydroxyzine Pamoate for Preventing Infusion Reactions to the First Dose of Rituximab in Patients With Non-Hodgkin Lymphoma: Protocol for a Phase II, Double-Blind, Multicenter Randomized Trial
CONCLUSIONS: This study is the first randomized controlled trial comparing the effects of oral first- and second-generation histamine H1-receptor antagonists in preventing IRs induced by the initial administration of rituximab. The findings from this study hold the potential to establish the rationale for a phase III study aimed at determining the standard premedication protocol for rituximab infusion.TRIAL REGISTRATION: Japan Registry of Clinical Trials jRCTs051220169; https://jrct.niph.go.jp/latest-detail/jRCTs051220169.INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): DERR1-10.2196/54882.PMID:38386393 | DOI:10.2196/54...
Source: Cancer Control - February 22, 2024 Category: Cancer & Oncology Authors: Yumi Kitahiro Kazuhiro Yamamoto Kimikazu Yakushijin Takeshi Ioroi Masaaki Tanda Kotaro Itohara Tomohiro Omura Hironobu Minami Ikuko Yano Source Type: research
The Effects of Genetic Polymorphism on Toxicity and Pharmacokinetics of Methotrexate in Egyptian Adult Patients with Leukaemia or Lymphoma
Xenobiotica. 2024 Feb 21:1-40. doi: 10.1080/00498254.2024.2320778. Online ahead of print.ABSTRACT1. Polymorphisms in genes coding folate-metabolizing enzymes might alter the pharmacokinetics and sensitivity for methotrexate "MTX".2. The aim of the study aimed to investigate the influence of MTHFR C677T, DHFR19 Ins/del, GGH -401 C > T, and MTR A2756G polymorphisms on MTX toxicity and pharmacokinetics in Egyptian patients with Acute lymphoblastic leukaemia (ALL) or Non-Hodgkin lymphoma (NHL).3. Fifty adult Egyptian patients with ALL and NHL, treated with high dose MTX, were prospectively enrolled in the study. Clinical an...
Source: Xenobiotica - February 21, 2024 Category: Research Authors: Khloud Shendy Khaled Abdelkawy Ahmed Amin Ali Fathalla Belal Mostafa Abdelhakiem Galal Magdy Nahla Anber Fawzy Elbarbry Source Type: research
The Effects of Genetic Polymorphism on Toxicity and Pharmacokinetics of Methotrexate in Egyptian Adult Patients with Leukaemia or Lymphoma
Xenobiotica. 2024 Feb 21:1-40. doi: 10.1080/00498254.2024.2320778. Online ahead of print.ABSTRACT1. Polymorphisms in genes coding folate-metabolizing enzymes might alter the pharmacokinetics and sensitivity for methotrexate "MTX".2. The aim of the study aimed to investigate the influence of MTHFR C677T, DHFR19 Ins/del, GGH -401 C > T, and MTR A2756G polymorphisms on MTX toxicity and pharmacokinetics in Egyptian patients with Acute lymphoblastic leukaemia (ALL) or Non-Hodgkin lymphoma (NHL).3. Fifty adult Egyptian patients with ALL and NHL, treated with high dose MTX, were prospectively enrolled in the study. Clinical an...
Source: Xenobiotica - February 21, 2024 Category: Research Authors: Khloud Shendy Khaled Abdelkawy Ahmed Amin Ali Fathalla Belal Mostafa Abdelhakiem Galal Magdy Nahla Anber Fawzy Elbarbry Source Type: research
Accumulation of circulating myeloid-derived suppressor cell subsets: predicting poor clinical efficacy and prognosis through T cell suppression in non-Hodgkin's lymphoma
In conclusion, our study demonstrates that the increased circulating MDSC subsets predict poor clinical efficacy and prognosis in NHL, potentially involving T cell suppression through MDSC subsets expansion. These findings indicate the potential of MDSC subsets as comprehensive diagnostic, prognostic biomarkers, and therapeutic targets for NHL.PMID:38369808 | DOI:10.1093/jleuko/qiae032 (Source: Journal of Leukocyte Biology)
Source: Journal of Leukocyte Biology - February 19, 2024 Category: Hematology Authors: Lian-Fang Pu Man-Man Li Xiang-Jiang Feng Tun Zhang Lin-Hui Hu Hui-Min Zheng Alice Charwudzi Yang-Yang Ding Jun Liu Ze-Lin Liu Shu-Dao Xiong Source Type: research
Accumulation of circulating myeloid-derived suppressor cell subsets: predicting poor clinical efficacy and prognosis through T cell suppression in non-Hodgkin's lymphoma
In conclusion, our study demonstrates that the increased circulating MDSC subsets predict poor clinical efficacy and prognosis in NHL, potentially involving T cell suppression through MDSC subsets expansion. These findings indicate the potential of MDSC subsets as comprehensive diagnostic, prognostic biomarkers, and therapeutic targets for NHL.PMID:38369808 | DOI:10.1093/jleuko/qiae032 (Source: Journal of Leukocyte Biology)
Source: Journal of Leukocyte Biology - February 19, 2024 Category: Hematology Authors: Lian-Fang Pu Man-Man Li Xiang-Jiang Feng Tun Zhang Lin-Hui Hu Hui-Min Zheng Alice Charwudzi Yang-Yang Ding Jun Liu Ze-Lin Liu Shu-Dao Xiong Source Type: research
Dihydrocelastrol induces cell death and suppresses angiogenesis through BCR/AP-1/junb signalling in diffuse large B cell lymphoma
Arch Biochem Biophys. 2024 Feb 15:109929. doi: 10.1016/j.abb.2024.109929. Online ahead of print.ABSTRACTDiffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma. Although treatment options have improved, a large proportion of patients show low survival rates, highlighting an urgent need for novel therapeutic strategies. The aim of this study was to investigate the efficacy of the new small-molecule compound dihydrocelastrol (DHCE), acquired through the structural modification of celastrol (CE), in the treatment of DLBCL. DHCE showed potent anti-lymphoma efficacy and synergistic effects with dox...
Source: Archives of Biochemistry and Biophysics - February 17, 2024 Category: Biochemistry Authors: Yue Lai Shushan Guo Qiongwei Tang Gaomei Chang Hui Zhang Bo Li Qilin Feng Ke Hu Zhijian Xu Xuejie Gao Qikai Zhang Hongfei Yi Dongliang Song Yifei Zhang Yu Peng Haiyan Cai Weiliang Zhu Jumei Shi Source Type: research
Safety and Toxicity Profiles of CAR T Cell Therapy in Non-Hodgkin Lymphoma: A Systematic Review and Meta-Analysis
The application of CD19-directed chimeric antigen receptor T (CAR T) cell therapy has improved outcomes for thousands of patients with non-Hodgkin B cell lymphoma (NHL). The toxicities associated with various CAR T cell products, however, can be severe and difficult to anticipate. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - February 16, 2024 Category: Hematology Authors: Samuel Yamshon, Caitlin Gribbin, Mohammad Alhomoud, Nora Chokr, Zhengming Chen, Michelle Demetres, Michelle Pasciolla, John Leonard, Tsiporah Shore, Peter Martin Tags: Original Study Source Type: research
Safety of a 90-min duration of intravenous infusion of obinutuzumab in patients with B-cell non-Hodgkin's lymphoma in a tertiary hospital in China: a prospective, open-label, exploratory clinical trial
This study aimed to analyze the safety and applicability of a 90-min duration of infusion (SDI) of obinutuzumab in patients with B-cell non-Hodgkin's lymphoma (NHL) in a tertiary hospital in China. This exploratory clinical trial was performed at Jiangsu Province Hospital. All patients were treated with the standard infusion regimen for the first infusion. If no grade ≥3 infusion-related reactions (IRRs) occurred, the subsequent infusions were given as SDI. The primary endpoint was the incidence of IRR during the standard infusion (3-4 h) and 90-min SDI regimens. This study enrolled 208 patients and all completed cycle 1...
Source: Braz J Med Biol Res - February 15, 2024 Category: Research Authors: Shuangshuang Xing Yiqin Pu Xiaoqian Zhao Yan Hu Feiyan Zhang Zejuan Gu Wei Xu Lei Fan Yi Miao Jianyong Li Source Type: research
Safety of a 90-min duration of intravenous infusion of obinutuzumab in patients with B-cell non-Hodgkin's lymphoma in a tertiary hospital in China: a prospective, open-label, exploratory clinical trial
This study aimed to analyze the safety and applicability of a 90-min duration of infusion (SDI) of obinutuzumab in patients with B-cell non-Hodgkin's lymphoma (NHL) in a tertiary hospital in China. This exploratory clinical trial was performed at Jiangsu Province Hospital. All patients were treated with the standard infusion regimen for the first infusion. If no grade ≥3 infusion-related reactions (IRRs) occurred, the subsequent infusions were given as SDI. The primary endpoint was the incidence of IRR during the standard infusion (3-4 h) and 90-min SDI regimens. This study enrolled 208 patients and all completed cycle 1...
Source: Brazilian Journal of Medical and Biological Research - February 15, 2024 Category: Research Authors: Shuangshuang Xing Yiqin Pu Xiaoqian Zhao Yan Hu Feiyan Zhang Zejuan Gu Wei Xu Lei Fan Yi Miao Jianyong Li Source Type: research
Safety of a 90-min duration of intravenous infusion of obinutuzumab in patients with B-cell non-Hodgkin's lymphoma in a tertiary hospital in China: a prospective, open-label, exploratory clinical trial
This study aimed to analyze the safety and applicability of a 90-min duration of infusion (SDI) of obinutuzumab in patients with B-cell non-Hodgkin's lymphoma (NHL) in a tertiary hospital in China. This exploratory clinical trial was performed at Jiangsu Province Hospital. All patients were treated with the standard infusion regimen for the first infusion. If no grade ≥3 infusion-related reactions (IRRs) occurred, the subsequent infusions were given as SDI. The primary endpoint was the incidence of IRR during the standard infusion (3-4 h) and 90-min SDI regimens. This study enrolled 208 patients and all completed cycle 1...
Source: Cell Research - February 15, 2024 Category: Cytology Authors: Shuangshuang Xing Yiqin Pu Xiaoqian Zhao Yan Hu Feiyan Zhang Zejuan Gu Wei Xu Lei Fan Yi Miao Jianyong Li Source Type: research
Safety of a 90-min duration of intravenous infusion of obinutuzumab in patients with B-cell non-Hodgkin's lymphoma in a tertiary hospital in China: a prospective, open-label, exploratory clinical trial
This study aimed to analyze the safety and applicability of a 90-min duration of infusion (SDI) of obinutuzumab in patients with B-cell non-Hodgkin's lymphoma (NHL) in a tertiary hospital in China. This exploratory clinical trial was performed at Jiangsu Province Hospital. All patients were treated with the standard infusion regimen for the first infusion. If no grade ≥3 infusion-related reactions (IRRs) occurred, the subsequent infusions were given as SDI. The primary endpoint was the incidence of IRR during the standard infusion (3-4 h) and 90-min SDI regimens. This study enrolled 208 patients and all completed cycle 1...
Source: Braz J Med Biol Res - February 15, 2024 Category: Research Authors: Shuangshuang Xing Yiqin Pu Xiaoqian Zhao Yan Hu Feiyan Zhang Zejuan Gu Wei Xu Lei Fan Yi Miao Jianyong Li Source Type: research
Safety of a 90-min duration of intravenous infusion of obinutuzumab in patients with B-cell non-Hodgkin's lymphoma in a tertiary hospital in China: a prospective, open-label, exploratory clinical trial
This study aimed to analyze the safety and applicability of a 90-min duration of infusion (SDI) of obinutuzumab in patients with B-cell non-Hodgkin's lymphoma (NHL) in a tertiary hospital in China. This exploratory clinical trial was performed at Jiangsu Province Hospital. All patients were treated with the standard infusion regimen for the first infusion. If no grade ≥3 infusion-related reactions (IRRs) occurred, the subsequent infusions were given as SDI. The primary endpoint was the incidence of IRR during the standard infusion (3-4 h) and 90-min SDI regimens. This study enrolled 208 patients and all completed cycle 1...
Source: Brazilian Journal of Medical and Biological Research - February 15, 2024 Category: Research Authors: Shuangshuang Xing Yiqin Pu Xiaoqian Zhao Yan Hu Feiyan Zhang Zejuan Gu Wei Xu Lei Fan Yi Miao Jianyong Li Source Type: research
Safety of a 90-min duration of intravenous infusion of obinutuzumab in patients with B-cell non-Hodgkin's lymphoma in a tertiary hospital in China: a prospective, open-label, exploratory clinical trial
This study aimed to analyze the safety and applicability of a 90-min duration of infusion (SDI) of obinutuzumab in patients with B-cell non-Hodgkin's lymphoma (NHL) in a tertiary hospital in China. This exploratory clinical trial was performed at Jiangsu Province Hospital. All patients were treated with the standard infusion regimen for the first infusion. If no grade ≥3 infusion-related reactions (IRRs) occurred, the subsequent infusions were given as SDI. The primary endpoint was the incidence of IRR during the standard infusion (3-4 h) and 90-min SDI regimens. This study enrolled 208 patients and all completed cycle 1...
Source: Braz J Med Biol Res - February 15, 2024 Category: Research Authors: Shuangshuang Xing Yiqin Pu Xiaoqian Zhao Yan Hu Feiyan Zhang Zejuan Gu Wei Xu Lei Fan Yi Miao Jianyong Li Source Type: research
Safety of a 90-min duration of intravenous infusion of obinutuzumab in patients with B-cell non-Hodgkin's lymphoma in a tertiary hospital in China: a prospective, open-label, exploratory clinical trial
This study aimed to analyze the safety and applicability of a 90-min duration of infusion (SDI) of obinutuzumab in patients with B-cell non-Hodgkin's lymphoma (NHL) in a tertiary hospital in China. This exploratory clinical trial was performed at Jiangsu Province Hospital. All patients were treated with the standard infusion regimen for the first infusion. If no grade ≥3 infusion-related reactions (IRRs) occurred, the subsequent infusions were given as SDI. The primary endpoint was the incidence of IRR during the standard infusion (3-4 h) and 90-min SDI regimens. This study enrolled 208 patients and all completed cycle 1...
Source: Brazilian Journal of Medical and Biological Research - February 15, 2024 Category: Research Authors: Shuangshuang Xing Yiqin Pu Xiaoqian Zhao Yan Hu Feiyan Zhang Zejuan Gu Wei Xu Lei Fan Yi Miao Jianyong Li Source Type: research
